Chemotherapy for enterohemorrhagic Escherichia coli O157:H infection in a mouse model.
The aim of this study is to evaluate the therapeutic effect of the antimicrobial agents, fosfomycin (FOM), minocycline (MINO), kanamycin (KM) and norfloxacin (NFLX) in the enterohemorrhagic Escherichia coli (EHEC) infected mouse model which we established previously (Infect. Immun. 62 (1994) 3447-3453). Each of the antimicrobial agents, 1/16 LD(50), was given to the mice per os (p.o. ) or intraperitoneally (i.p.) for 3 days after bacterial inoculation and then we observed their mortality rate for 2 weeks. The mortality rates of mice administered with MINO (p.o./i.p.), KM (p.o.), NFLX (p. o./i.p.) were significantly lower than those of the control group. Both the bacterial number and VT2c level in the feces of the FOM group were lower than those of the NFLX group on day 1, but reversed on day 3. In an in vitro experiment, each of the four drugs in combination with mitomycin C (MMC) caused a more significant decrease in the bacterial number than sole MMC, and they consequently indicated the suppressive effect on the release of VT2c.
Yoshimura
K
K
Department of Microbiology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Fujii
J
J
Taniguchi
H
H
Yoshida
S
S
D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001427:Bacterial Toxins / Q000032:analysis; D015169:Colony Count, Microbial; D004357:Drug Synergism; D004768:Enterotoxins / Q000032:analysis; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000401:mortality; D019453:Escherichia coli O157 / Q000187:drug effects*; D005243:Feces / Q000737:chemistry / Q000382:microbiology; D005578:Fosfomycin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D007274:Injections, Intraperitoneal; D007612:Kanamycin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008911:Minocycline / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D016685:Mitomycin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D009643:Norfloxacin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D022641:Shiga Toxin 2
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001427:Bacterial Toxins; D004768:Enterotoxins; D022641:Shiga Toxin 2; D005578:Fosfomycin; D016685:Mitomycin; D007612:Kanamycin; D008911:Minocycline; D009643:Norfloxacin